NA-Semax Amidate
Also known as: N-Acetyl Semax Amidate, NASA peptide, Modified Semax
Grey-Market Compound. This compound is not approved by the FDA or any major regulatory authority. No established regimen exists. Products available outside of regulated channels lack standardized manufacturing, quality control, and potency verification. Consult a qualified clinician. Research-only risks apply.
Overview
Clinical Summary
NA-Semax Amidate is a chemically modified derivative of Semax, the Russian-developed heptapeptide analogue of ACTH(4-10). The modifications include an N-acetyl group at the amino terminus and an amide group at the carboxy terminus, which are designed to increase enzymatic stability and extend the biological half-life compared to native Semax. The parent compound Semax is approved in Russia for stroke and cognitive disorders, but NA-Semax Amidate itself has not been independently studied in clinical trials. Its pharmacological profile is extrapolated from Semax research.
Plain Language Summary
NA-Semax Amidate is a modified version of Semax, a brain-protective peptide approved in Russia. The chemical modifications are intended to make it last longer in the body and be more potent. While the original Semax has some clinical trial data from Russia, this specific modified version has not been tested in its own clinical studies. It is available through grey-market vendors and is used intranasally.
Mechanism of Action
NA-Semax Amidate shares the core mechanism of Semax: it is an analogue of the ACTH(4-10) fragment that modulates melanocortin receptors (MC3R and MC4R) and neurotrophic signaling. The primary neurotropic effects include upregulation of BDNF and NGF expression in the hippocampus and cortex, modulation of serotonergic and dopaminergic neurotransmission, and anti-inflammatory effects via suppression of IL-6 and TNF-alpha. The N-acetyl modification reduces aminopeptidase degradation, while the C-terminal amidation prevents carboxypeptidase cleavage. Together, these modifications are proposed to extend the effective duration and enhance blood-brain barrier penetration compared to unmodified Semax.
Evidence Summary
No clinical trials have been conducted specifically on NA-Semax Amidate. Evidence is extrapolated from the parent compound Semax, which has been studied in Russian clinical trials for acute ischemic stroke (Gusev et al., 2005) and cognitive enhancement. Modified analogues including acetylated forms have shown enhanced neuroprotective activity in rodent stroke models (Dolotov et al., 2015). The specific pharmacokinetic advantages of the NA-Amidate modification over native Semax have not been quantified in human studies.
Safety Profile
Safety data are extrapolated from the parent compound Semax, which has a favorable safety profile in Russian clinical use. Semax has been used intranasally in Russia for over two decades with reported good tolerability. However, the specific modifications in NA-Semax Amidate could alter the safety profile in unpredictable ways. No independent safety evaluation of the modified form exists.
Contraindications
- Known hypersensitivity to Semax or ACTH-derived peptides
- Acute psychosis (melanocortin modulation may affect mood)
- Pregnancy and breastfeeding (no safety data for this specific form)
Adverse Events
- Nasal irritation (most common, from intranasal administration)
- Headache (mild, reported with parent compound)
- Irritability or overstimulation (rare, reported with parent compound)
- Insomnia if administered late in the day (anecdotal)
Interactions
- Theoretical interaction with melanocortin receptor modulators
- May potentiate stimulant effects of other nootropics
- No formal interaction studies for this specific modification
Regulatory Notes
NA-Semax Amidate is not approved in any jurisdiction. The parent compound Semax is approved in Russia and Ukraine but not in the US, EU, or other Western regulatory systems. NA-Semax Amidate is available through grey-market peptide vendors, typically as a nasal spray. No GMP manufacturing standards apply to these products.
Monitoring Considerations
No established monitoring guidelines specific to NA-Semax Amidate. Based on the parent compound, monitoring cognitive function, mood, and sleep quality may be reasonable. No specific laboratory tests are required based on available data.
These are general considerations for clinical awareness and do not constitute prescriptive monitoring recommendations for any individual patient.
Stability and Handling Notes
Grey-market preparations are supplied as nasal spray solutions or lyophilized powder. Vendor recommendations (not validated) suggest refrigerated storage at 2 to 8 degrees C. Nasal spray solutions may have limited stability after opening. No pharmacopeial stability data exist for this specific modification.
References
- 1review
Modified Analogues of ACTH(4-10): Pharmacological Profiles of Semax and Its Derivatives
Levitskaya NG, Glazova NY, Sebentsova EA, et al. (2019). Neurochemical Journal
Key findings: Review of Semax derivatives including acetylated and amidated forms. N-acetyl modification may enhance enzymatic stability and blood-brain barrier penetration. Amidation reduces carboxypeptidase degradation.
Limitations: Based on parent compound data extrapolation. No independent clinical trials on NA-Semax Amidate specifically.
- 2preclinical
Comparative Neuroprotective Effects of Semax Analogues in Cerebral Ischemia Models
Dolotov OV, Karpenko EA, et al. (2015). Doklady Biological Sciences
Key findings: Modified Semax analogues including acetylated forms demonstrated enhanced neuroprotective activity in rodent stroke models compared to unmodified Semax, with longer duration of BDNF upregulation.
Limitations: Russian language primary data. Animal models only. Specific NA-Semax Amidate form not always distinguished from other analogues.
Last reviewed: 2026-03-24 | Version: 1 | Status: Published
More in Cognitive
Semax
ACTH(4-7)-Pro-Gly-Pro · Semax 1%
Semax is a lab-made peptide based on a fragment of a natural brain hormone (ACTH). It was developed in Russia, where it is an approved medication for brain protection after stroke and for cognitive enhancement. It is given as a nasal spray. In Western countries it is not approved but is available in the grey market as a nootropic (brain-boosting) peptide.
Selank
TP-7 · Thr-Lys-Pro-Arg-Pro-Gly-Pro
Selank is a lab-made peptide based on a natural immune peptide called tuftsin, developed in Russia where it is approved for anxiety and cognitive support. It is given as a nasal spray and is notable for reducing anxiety without causing drowsiness or sedation. It is not approved in Western countries but is available in the grey market.
Dihexa
N-hexanoic-Tyr-Ile-(6) aminohexanoic amide · Norleual
Dihexa is a research peptide that was developed to improve brain function by boosting a growth factor pathway involved in forming new brain connections. In animal studies, it improved memory and learning at remarkably low doses. It has never been tested in humans, and its safety in people is completely unknown. It is available only through grey-market sources without any quality assurance.
Want to discuss this compound with a qualified physician?
The Peptide Association has verified over 160 licensed providers specializing in peptide therapy, with telehealth options available in most states.
Find a Verified Provider